Sodium oxybate

Drug Profile

Sodium oxybate

Alternative Names: Gamma-hydroxybutyrate; JZP-6; KEY-10; NSC-84223; Xyrem

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Jazz Pharmaceuticals
  • Developer Jazz Pharmaceuticals; Jazz Pharmaceuticals Inc; Jazz Pharmaceuticals plc; UCB; Valeant Pharmaceuticals International
  • Class Hydroxybutyrates; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cataplexy; Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cataplexy; Narcolepsy
  • Discontinued Essential tremor; Fibromyalgia

Most Recent Events

  • 05 Apr 2017 Jazz Pharmaceuticals enters into settlement agreement with Hikma Pharmaceuticals related to marketing of generic version of sodium oxybate in USA
  • 29 Nov 2016 Jazz Pharmaceuticals announces intention to submit sNDA to the US FDA in late 2017 (Jazz Pharmaceuticals pipeline, November 2016)
  • 08 Nov 2016 Jazz Pharmaceuticals completes enrolment in the phase II trial for Narcolepsy (In adolescents, In children) in (US, Finland, France, Italy,Netherlands) (NCT02221869)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top